SCHEMBL2675780

SCHEMBL2675780

CCN1CCN(Cc2c(C(=O)O)c3ccccc3c(=O)n2-c2ccccc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
MAPT P10636 2/20 0.44
NPSR1 Q6W5P4 4/20 0.43
TSHR P16473 1/20 0.43
P4HB P07237 1/20 0.43
CHRNA7 P36544 1/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
PGR P06401 1/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
RECQL P46063 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HSD11B1 P28845 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2677324 0.90 MAPT (0.51) ALDH1A1MAPTNPSR1TSHRP4HB
SCHEMBL2676766 0.89 MCL1 (0.46) ALDH1A1MAPTNPSR1MAPK1L3MBTL1
SCHEMBL2676392 0.89 MAPK1 (0.45) ALDH1A1MAPTNPSR1TSHRP4HB
SCHEMBL2675569 0.89 ALDH1A1 (0.46) ALDH1A1MAPTNPSR1TSHRP4HB
SCHEMBL2677217 0.89 ALDH1A1 (0.47) ALDH1A1MAPTNPSR1TSHRP4HB
SCHEMBL2676747 0.88 HSP90AA1 (0.48) ALDH1A1MAPTNPSR1TSHRP4HB
SCHEMBL2677517 0.88 ALDH1A1 (0.47) ALDH1A1MAPTNPSR1TSHRMAPK1
SCHEMBL2676750 0.88 ALDH1A1 (0.47) ALDH1A1MAPTNPSR1TSHRMAPK1
SCHEMBL2676371 0.88 MAPT (0.41) ALDH1A1MAPTNPSR1TSHRP4HB
SCHEMBL3631253 0.88 P4HB (0.44) MAPTNPSR1TSHRP4HBHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 ALDH1A1 2304/4885MAPT 3659/4885NPSR1 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.